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Programs that control immune cell homeostasis are orchestrated through the coordinated action of
a number of regulatory cell populations, including regulatory T cells, regulatory B cells, myeloid-
derived suppressor cells, alternatively-activated macrophages and tolerogenic dendritic cells.
These regulatory cell populations can prevent harmful inflammation following completion of pro-
tective responses and thwart the development of autoimmune pathology. However, they also have
a detrimental role in cancer by favoring escape from immune surveillance. One of the hallmarks of
regulatory cells is their remarkable plasticity as they can be positively or negatively modulated by a
plethora of cytokines, growth factors and co-stimulatory signals that tailor their differentiation, sta-
bility and survival. Here we focus on the emerging roles of galectins, a family of highly conserved
glycan-binding proteins in regulating the fate and function of regulatory immune cell populations,
both of lymphoid andmyeloid origins. Given the broad distribution of circulating and tissue-specific
galectins, understanding the relevance of lectin–glycan interactions in shaping regulatory cell com-
partments will contribute to the design of novel therapeutic strategies aimed at modulating their
function in a broad range of immunological disorders.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
1.1. Immune cell homeostatic programs regulated by galectin–glycan
interactions: the ‘sweet’ sound of silence
The immune system has evolved to mount an effective defense
against pathogens and tumors and to minimize deleterious inflam-
mation caused by commensal microorganisms and immune
responses against self and environmental antigens. Programs that
safeguard immune cell homeostasis are required for resetting host
protective immunity to steady-state conditions, and for preserving
immune tolerance, while preventing autoimmune and allergic
reactions, maintaining fetal survival during pregnancy and sup-
pressing metabolic inflammation [1]. However, the same regula-
tory programs may be usurped by tumors or pathogens to evade
immune responses [2]. During the past decades a number of regu-latory cell populations, belonging to lymphoid or myeloid lineages,
have been shown to be instrumental for preserving and restoring
immune cell homeostasis by controlling the fate of innate and
adaptive effector cells. These include, among others, different types
and subsets of naturally-occurring or inducible regulatory T cells
(Tregs), regulatory B cells (Bregs), myeloid-derived suppressor
cells (MDSCs), M2-type macrophages and tolerogenic dendritic
cells (DCs) [3–7]. Moreover, recent studies highlighted the
immunosuppressive potential of other cell types including uterine
natural killer (uNK) cells and mesenchymal stem cells (MSCs) [8,9].
One of the hallmarks of regulatory cell populations is their remark-
able plasticity as they can be positively or negatively modulated by
a broad spectrum of cytokines, chemokines, growth factors and co-
stimulatory signals that tailor their differentiation, expansion, sta-
bility and survival [10]. Moreover, although underappreciated for
many years, emerging observations suggest essential roles for
endogenous glycan-binding proteins or lectins and their corre-
sponding glycosylated ligands in controlling the fate and function
of immune regulatory cells [11].
Among the various lectin families, galectins are probably the
most conserved throughout the evolution, with members identi-
fied in most animal taxa examined so far [12]. Although galectins
do not have the signal sequence required for the classical secretory
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tional pathway that is still poorly understood [13]. Fifteen mem-
bers of the galectin (Gal) family, divided into three different sub-
families, have been identified in a variety of cells and tissues: a)
‘proto-type’ galectins (Gal-1, -2, -5, -7, -10, -11, -13, -14 and -15)
have one carbohydrate recognition domain (CRD) that can dimer-
ize, b) ‘tandem-repeat’ galectins (Gal-4, -6, -8, -9 and -12) contain
two homologous CRDs in tandem in a single polypeptide chain and
c) the ‘chimera-type’ Gal-3 which contains a CRD connected to a
non-lectin N-terminal region that is responsible for oligomeriza-
tion [14].
Although galectins can recognize complex glycan determinants
with relatively high affinity in the submicromolar range [15], it is
their ability to dimerize or oligomerize, together with the struc-
ture, number and density of glycan epitopes in multivalent glyco-
proteins, which determine the avidity of galectin–glycan
interactions and their signaling potency [16]. Interestingly, galec-
tins play critical roles outside the cells by interacting with a variety
of glycosylated ligands on the cell surface and the extracellular
matrix [11]. Once in the extracellular milieu, galectins can regulate
cell proliferation, signaling, apoptosis and trafficking and modulate
critical physiologic and pathologic processes including inflamma-
tion, angiogenesis, tumorigenesis and neurodegeneration [17,18].
However, these lectins can also play roles inside the cells including
modulation of cell survival, intracellular immunity, clathrin-
independent endocytosis, signaling, mRNA splicing and autophagy
[19–21].
Interestingly, analysis of the molecular and biochemical deter-
minants of purified galectins and glycans revealed the formation
of two- and three-dimensional arrangements of multivalent struc-
tures often termed ‘lattices’ [22]. These multivalent lectin–glycan
complexes have been proposed to serve as scaffolds for organizing
cell surface domains, which in turn modulate the signaling thresh-
old of relevant surface glycoproteins including the T cell receptor
(TCR), B cell receptor (BCR), cytokine receptors (e.g. transforming
growth factor (TGF)-b RII), ion channels (e.g. transient receptor
potential cation channel subfamily V member 5; TRPV5), mem-
brane transporters (e.g. glucose transporter 2; GLUT-2) and growth
factor receptors (e.g. vascular endothelial growth factor receptor 2;
VEGFR2) [11,23,24]. Regarding their saccharide specificity, galec-
tins were first defined by their common ability to recognize the
disaccharide N-acetyllactosamine [Galb(1–4)-GlcNAc; LacNAc].
However, recent evidence revealed substantial differences in the
glycan-binding preferences of individual members of the galectin
family [14,25,26]. Illustrating this concept, Gal-1 binds to non-
sialylated and a2,3-sialylated, but not a 2,6-sialylated glycans,
whereas Gal-3 binds either a 2,3- or a 2,6-sialylated glycans and
Gal-2 exhibits reduced binding to all sialylated glycans. Moreover,
Gal-8 has higher affinity for 30-O-sulfated or 30-O-sialylated gly-
cans and Lewis X-containing glycans than for LacNAc-
terminating oligosaccharides, while Gal-10 surprisingly recognizes
mannose-containing ligands [11]. Interestingly, different factors
may control the biological activity of galectins including: (a) their
oligomerization status (monomeric versus dimeric or oligomeric
forms); (b) their subcellular compartmentalization (nuclear, cyto-
plasmic or extracellular localization); (c) their stability in reducing
or oxidative microenvironments and (d) the active remodeling of
N- and O-glycans on target cells [18,27].
The contribution of galectins and glycosylated ligands to innate
and adaptive immune responses, particularly effector T cell
responses, has been reviewed elsewhere [28–31]. Here we focus
on the relevance of galectins and glycans in regulating the fate
and function of lymphoid and myeloid regulatory cell populations
including Tregs, Bregs, tolerogenic DCs, M2-type macrophages and
MDSCs.2. Regulatory T cells
Regulatory T cells are key players in maintaining the balance
between immune activation and tolerance. They can shut-off exu-
berant or undesired immune responses by restraining inflamma-
tion to self antigens, commensal microbiota, allergens, and
pathogens, thus preventing autoimmune and autoinflammatory
disorders. The so-called, inducible CD4+ regulatory T cells (iTregs)
are generated outside the thymic compartment to regulate periph-
eral immune tolerance, whereas thymus-derived naturally-
occurring CD4+ regulatory T cells (nTregs) are generated in the thy-
mus. Depending on whether they stably express the forkhead box
P3 (Foxp3) transcription factor, iTregs may be divided into two
subsets: the classical TGF-b-induced CD4+Foxp3+ Tregs and the
CD4+Foxp3 type 1 regulatory T (Tr1) cells [32]. From a functional
viewpoint, Tregs can suppress T cell responses through different,
although potentially overlapping mechanisms including the syn-
thesis of inhibitory cytokines (interleukin (IL)-10, IL-35, TGF-b),
suppression by cytolysis (perforin- and granzyme-dependent path-
ways), inhibition by metabolic disruption (IL-2 deprivation), and
modulation of DC function (i.e. tryptophan depletion via induction
of indoleamine 2,3-dioxygenase; IDO) [3]. Development of Tregs,
either in the thymus or peripheral compartments, as well as their
stability and function, all depend on the right combination of intra-
cellular signals and environmental cues, including cytokines,
chemokines, microbial products and metabolites [3].
Under this complex scenario, galectins and their ligands have
emerged as novel regulators of Tregs biology and mediators of
their immunosuppressive activity. In microarray analysis, the
LGALS1 gene, encoding Gal-1, was found to be up-regulated in
Tregs compared to activated effector T cells [33]. Garin and col-
leagues confirmed the abundance of Gal-1 protein in Foxp3+ Tregs
and provided evidence of its contribution to the suppressive activ-
ity of these cells. Targeted disruption of Gal-1, using biochemical or
genetic approaches, attenuated the inhibitory effects of human and
mouse CD4+CD25+ Tregs, suggesting the involvement of this lectin
in Treg cell-mediated immunosuppression [34]. Further mechanis-
tic analysis demonstrated that Foxp3+ Tregs utilize Gal-1 to tran-
siently inhibit PI3K/p21ras activity in human CD8+ T cells despite
partial activation of TCR proximal signals, such as phosphorylation
of CD3f, zeta-chain-associated protein kinase 70 (Zap70), linker of
activated T cells (LAT) and protein kinase C/ (PKC/), leading to
CD8+ T cell dysfunction [35]. Interestingly, Wang et al. showed that
Treg-derived Gal-1 dampens effector T cell responses through
cross-linking of the monosialotetrahexosylganglioside (GM1),
resulting in activation of the short transient receptor potential
channel 5 (TRPC5) and modulation of Ca2+ influx [36]. Thus, target-
ing Gal-1 synthesis in Tregs may contribute to attenuate the sup-
pressive potential of these cells, leading to stimulation of anti-
tumor and anti-microbial T cell-mediated immunity. On the other
hand, reinforcing Gal-1 expression would lead to generation of
Tregs with enhanced immunosuppressive activity in settings of
chronic inflammation, autoimmune disease and organ
transplantation.
However, this regulatory mechanism does not seem to be lim-
ited to Gal-1, as other members of the galectin family have also
been shown to be up-regulated in Tregs. In fact, LGALS3, the gene
encoding Gal-3, is selectively increased in human Tregs, as com-
pared to human T helper (Th) cells through a transcriptional mech-
anism involving the gene expressing ubiquitin D (UBD), a
downstream element of Foxp3 [37]. Interestingly, proteomic anal-
ysis of human CD4+CD25+Foxp3+ Tregs identified Gal-10 as a novel
marker that delineates this cell population from resting and acti-
vated CD4+ T cells. Targeted inhibition of Gal-10 restored the pro-
liferative capacity of human Tregs and abrogated their suppressive
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Fig. 1. Impact of galectins in the modulation of Treg cell programs. Naïve T cells (T naïve) and naturally-occurring regulatory T cells (nTregs) emigrate from the thymus to
lymph nodes. Dendritic cells (DCs) reach the lymph nodes via afferent lymphatic vessels following processing of microbial and tumor antigens. Upon antigen presentation,
TCR signaling and local cytokines contribute to activation and differentiation of effector T cells (Teff), which readily migrate to peripheral tissues to eradicate pathological
threats. However, different stimuli, including members of the galectin family instruct differentiation of naïve T cells toward a regulatory phenotype. Galectin (GAL)-1 favors
differentiation of naïve T cells into Foxp3IL-10+ Tr1 regulatory cells. GAL-1 is up-regulated in inducible Tregs (iTregs) and nTregs, and contributes to their
immunosuppressive activity. GAL-3 inhibits differentiation of naïve T cells into iTregs, whereas GAL-8 and GAL-9 enhance the iTreg profile and suppress Teff activity. Studies
also showed that GAL-10 contributes to the suppressive function of human Tregs.
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as a ligand for the T cell immunoglobulin mucin-3 (Tim-3) recep-
tor, was up-regulated on mouse CD4+CD25+Foxp3+ Tregs and pos-
itively modulated their function. Blockade of the Tim-3-Gal-9
pathway counteracted the suppressive activity of Tregs, enhanced
Th1 cytokine production in vitro and abrogated survival of allo-
geneic skin grafts induced by Tregs in vivo [39]. Furthermore,
recent studies demonstrated that hepatic Foxp3+ Tregs promoted
liver T cell homeostasis in a model of concanavalin A-induced hep-
atitis via up-regulation of Gal-9 [40]. Likewise, Gal-9-expressing
Tregs promote the exhaustion of Tim-3+ T cells in patients persis-
tently infected with hepatitis C virus (HCV) [41]. The mechanisms
underlying these effects were recently revealed by Wu and col-
leagues, who showed that expression of Gal-9 was crucial for the
generation of iTregs, but not nTregs. The authors found that activa-
tion of the Smad3 transcription factor induced expression of this
lectin and modulated iTreg cell stability and function through
direct association with a molecular complex involving CD44 and
TGF-b RI [42]. Thus, distinct members of the galectin family,
including Gal-1, -3, -9 and -10, are up-regulated in Tregs and
may influence their immunosuppressive function.
In a large number of experimental models of autoimmune dis-
ease and chronic inflammation, including collagen-induced arthri-
tis (CIA), experimental autoimmune encephalomyelitis (EAE),
experimental autoimmune uveitis (EAU), experimental diabetes,
inflammatory bowel disease (IBD), experimental autoimmune
orchitis (EAO) and graft versus host disease (GvHD), in vivo admin-
istration of recombinant Gal-1 or its genetic delivery attenuated
the clinical severity of the disease and tilted the balance toward
an anti-inflammatory cytokine profile [43–49]. On the other hand,
silencing of Gal-1 gene expression or antibody-mediated Gal-1
blockade suppressed tumor growth and/or metastasis and pro-
moted T cell-mediated tumor rejection in a variety of cancers
including melanoma, lung adenocarcinoma, pancreatic adenocarci-
noma, Hodgkin’s lymphoma, neuroblastoma, mammary adenocar-cinoma, Kaposi’s sarcoma, glioblastoma and ovary carcinoma
[24,50–58]. Seeking for potential mechanisms that could explain
the broad immunosuppressive activity of this b-galactoside-
binding lectin [59], we found, in a model of autoimmune ocular
inflammation, that Gal-1 therapy increased the frequency of Fox-
p3 Tr1 cells, which suppressed retinal disease when adoptively
transferred into immunized mice [45]. Moreover, Foxp3+ Tregs
were also expanded following administration of recombinant
Gal-1 in a lupus-like model [60]. In vitro, Gal-1 increased the rela-
tive abundance of CD4+CD25+Foxp3+ Tregs in co-cultures with
Reed Sternberg cells [53]. Interestingly, in a breast cancer model,
silencing tumor-derived Gal-1, using small hairpin ribonucleic acid
(shRNA) strategies, reduced the frequency of CD4+CD25+Foxp3+
Tregs within the tumor, draining lymph nodes, spleen, and lung
metastases, attenuated the immunosuppressive activity of Tregs
and selectively lowered expression of the regulatory molecule
LAT [55]. Likewise, in a mouse model of stress-induced failing
pregnancies in vivo and in co-cultures of human trophoblasts
and T cells in vitro, Gal-1 favored the induction of Foxp3-
dependent Treg cell programs [61,62]. Notably, Gal-1 was prefer-
entially expressed either by trophoblast cells or by uNK cells,
which play key roles in maintenance of placental immune privilege
[63]. These effects were confirmed in studies demonstrating that
Gal-1 controls cardiac inflammation and suppresses acute myocar-
dial infarction by increasing the frequency of Tregs in cardiac tissue
[64]. Thus, in addition to the well-established immune regulatory
roles of this lectin, mediated by induction of Th1 and Th17 cell
apoptosis [44], regulation of cytokine secretion [65] and inhibition
of T cell trafficking [28], Gal-1 also contributes to create immuno-
suppressive microenvironments via induction of Foxp3+ Tregs and
Foxp3 Tr1 cells.
Moreover, in a model of autoimmune uveitis, Gal-8 increased
the number of Tregs in both the draining lymph node and the
inflamed retina. In vivo generated Gal-8-induced Tregs expressed
the inhibitory coreceptor cytotoxic T lymphocyte antigen (CTLA)-
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Fig. 2. Impact of galectins in the control of regulatory myeloid cells. Upon interactions with stromal cells, cytokines and growth factors, myeloid cells can differentiate and
emigrate from the bone marrow to colonize peripheral tissues and orchestrate innate immune responses. However, given their plasticity, immunogenic myeloid cells (pink)
can also display regulatory or tolerogenic activity (blue). Galectin (GAL)-1 and GAL-9 stimulate M2-type polarization in macrophages, enhancing arginase (ARG) activity and
supporting anti-inflammatory functions. On the other hand, GAL-2 and GAL-3 can polarize macrophages toward an M1 phenotype, characterized by high iNOS activity and
pro-inflammatory function. Within the DC compartment, GAL-1 and GAL-3 can instruct these cells to become tolerogenic, while GAL-9 favors an immunogenic profile.
Whereas GAL-1 increases conversion of immature myeloid cells (IMCs) into Ly-6G+ MDSCs, GAL-9 favors differentiation into Ly-6G+ and Ly-6C+ MDSC profiles. Within the
Central Nervous System (CNS), astrocytes synthesize high amounts of GAL-1 which, upon binding to CD45 on microglia cells, favors their polarization into an M2-type profile
(Mi2), thereby preventing demyelination and inflammation-induced neurodegeneration. In contrast, GAL-9 shifts the balance toward an M1 (Mi1) pro-inflammatory
phenotype.
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integrin CD103 [66]. In vitro analysis of the mechanisms underly-
ing Gal-8 effects revealed the ability of this lectin to activate the
TGF-b pathway and sustain IL-2 receptor signaling [67]. Interest-
ingly, the Gal-9-Tim-3 axis can also modulate Treg cell biology.
Seki and colleagues found that recombinant Gal-9 suppressed clin-
ical signs of arthritis, reduced the number of Tim-3+CD4+ T cells
and promoted differentiation of naïve T cells into Tregs in vitro
[68]. Moreover, Gal-9 favored the expansion and proliferation of
Foxp3+ Tregs in a model of myocarditis [69], and contributed to
the immunosuppressive activity of HCV-infected hepatocytes
[70]. Furthermore, in response to Toll-like receptor (TLR)9 ligands
and non-digestible oligosaccharides, Gal-9 released by intestinal
epithelial cells favored Treg cell polarization [71]. These regulatory
effects were recently confirmed by intranasal administration of
Gal-9-expressing adenoviral associated virus (rAAV) into mice
infected with respiratory syncytial virus (RSV). Genetic delivery
of Gal-9 decreased viral load, and reduced the severity of lung
pathology through mechanisms involving expansion of Tregs
[72]. Analysis of the intracellular pathways triggered by Gal-9
revealed the ability of this lectin to enhance TGF-b1-induced phos-
phorylation of Smad2/3 and extracellular signal-regulated kinases1/2 (ERK1/2) [73]. In contrast to the positive role of Gal-1, -8- and -
9 in promoting Treg cell differentiation and augmenting their sup-
pressive activity, Gal-3 mostly displayed inhibitory effects within
the Treg cell compartment. In a model of autoimmune neuroin-
flammation, Gal-3 deficiency reduced the clinical symptoms of
the disease and increased the frequency of Foxp3+ Tregs in the cen-
tral nervous system (CNS), suggesting a major pro-inflammatory
role for this lectin [74]. Supporting these findings, Gal-3 also
reduced the frequency and function of CD4+CD25+Foxp3+ Tregs in
a model of Leishmania major infection via modulation of the Notch
signaling pathway [75].
Collectively, these data imply that a coordinated galectin pro-
gram may control Treg cell biology by regulating their differentia-
tion, expansion, stability and immunosuppressive activity (see
Fig. 1). Whether these glycan-binding proteins are transcription-
ally or epigenetically regulated during the lifespan of Tregs in dis-
tinct physiologic and/or pathologic settings still remains to be
elucidated. Moreover, further studies are warranted to investigate
the differential contribution of individual members of the galectin
family to Treg cell trafficking, expansion and tissue distribution
and their selective involvement in nTregs versus iTregs
compartments.
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In addition to their well-established roles in antigen recognition
and processing and their unique function as precursors of
immunoglobulin-producing plasma cells, B cells may also become
regulatory suppressing immunopathology, silencing the expansion
of pathogenic T and B cells and supporting immunological toler-
ance through the production of IL-10, IL-35, and TGF-b [76]. Stud-
ies in experimental animal models, as well as in patients with
autoimmune and infectious diseases, have identified multiple Breg
subsets induced in response to inflammation, which arise at differ-
ent stages of B cell development and exhibit diverse mechanisms
of immune suppression [76].
We have demonstrated that, upon BCR engagement, B cells syn-
thesize and secrete elevated amounts of Gal-1 to dampen the sur-
vival of neighboring activated T cells [77]. Moreover, intracellular
Gal-1 has been shown to interact with the B cell-specific transcrip-
tional coactivator Oct binding factor (OBF)-1-OCA-B and negatively
regulated B cell proliferation and tyrosine phosphorylation upon
BCR stimulation [78], suggesting that this lectin can restrain T cell
and B cell signaling. However, exposure of human chronic lympho-
cytic leukemia (CLL) B cells to extracellular Gal-1 supported tonic B
cell signaling [79], an effect that was recently confirmed by phos-
phoproteomic analysis of mature B cells [80]. Thus, intracellular
and extracellular Gal-1 may play different roles in modulating
mature B cell fate.
Interestingly, Clark and collaborators identified Gal-1 (LGALS1)
and Gal-3 (LGALS3) as genes that were differentially transcribed
in anergic B cells [81]. The authors further demonstrated that mice
lacking Gal-1 or Gal-3 showed subtle differences in B cell tolerance
[82], suggesting that galectin deficiency may impact B cell tolero-
genic circuits in combination with other factors, including epige-
netic and/or environmental mechanisms. Moreover, Gal-1 was
found to be up-regulated in IgM+ memory B cells and contributed
to B cell apoptosis through inhibition of Akt phosphorylation and
up-regulation of the BH3-only protein Bim [83], thus substantiating
the key regulatory role of galectins within the mature B cell com-
partment. Interestingly, although Gal-1 suppressed mature B cell
signaling, it increased plasma cell differentiation and survival, sug-
gesting that this lectin may be part of the intracellular signaling
machinery that governs B cell decisions [84,85]. This regulatory
effect appears to be restricted to Gal-1 as other members of the
galectin family have been proposed to play opposite role in plasma
cell biology. In fact, Gal-9 promoted plasma cell apoptosis [86] and
intracellular Gal-3 has been reported to skew the balance toward a
memory B cell phenotype [87]. Following antigen challenge, Gal-3
deficiency led to enhanced plasma cell differentiation and
unleashed immunoglobulin production, both in B1 and B2 cells
[87,88]. Finally, elegant studies reported that, during B-cell devel-
opment, Gal-1 secreted by bone marrow stromal cells acts as a
pre-B cell receptor ligand to modulate B cell maturation through
mechanisms involving displacement of Gal-1/glycan lattices and
shift toward a glycosylation-independent Gal-1-mediated pro-
tein–protein interaction [89]. Thus, although not investigated in
such detail as the T cell compartment, these studies suggest that
galectins may play different regulatory roles during the lifespan
of B cells, targeting their maturation, differentiation, signaling, tol-
erance and survival.
4. Tolerogenic dendritic cells
In spite of their traditional role in orchestrating adaptive
immune responses, conventional DC subsets, including myeloid
DCs and plasmacytoid DCs, can also attenuate inflammatory reac-
tions by promoting T cell anergy or by favoring the expansion, dif-ferentiation and/or recruitment of Tregs or Bregs [90]. During the
course of chronic inflammatory reactions, bidirectional interac-
tions take place between DCs and T cells, which may initiate either
immunogenic or tolerogenic circuits [91,92]. Several stimuli may
influence the decision of DCs to become tolerogenic, including IL-
10, TGF-b, vasoactive intestinal peptide (VIP) and 1,25-
dihydroxyvitamin D3. In addition, interaction with stromal cells,
CD4+CD25+Foxp3+ Tregs or apoptotic cells may also drive the dif-
ferentiation of tolerogenic DCs [91].
We found that both human and mouse DCs differentiated or
matured in a Gal-1-enriched microenvironment acquired a distinc-
tive regulatory or tolerogenic signature characterized by low
expression of CD11c (mouse DCs) or CD1a (human DCs), high
expression of the cell surface marker CD45RB, phosphorylation of
the transcription factor signal transducers and activators of tran-
scription (STAT)-3 and abundant secretion of IL-27 and IL-10
[93]. When transferred in vivo, these DCs promoted T-cell toler-
ance in antigen-specific settings, blunted Th1 and Th17 responses
and halted autoimmune CNS inflammation through mechanisms
involving DC-derived IL-27 and T cell-derived IL-10. Thus, using
IL-27 receptor-deficient (Il27ra/) and IL-10-deficient (Il10/)
mice, our results identified an immunoregulatory circuit linking
Gal-1 signaling, IL-27-producing tolerogenic DCs and IL-10 secret-
ing Tregs [93]. Induction of regulatory DCs by Gal-1 also con-
tributed to immune tolerance in settings of cancer and
pregnancy [54,61,94]. In fact, Kuo et al. found that lung cancer
derived-Gal-1 promoted tolerogenic DCs, which in turn favored
the induction of CD4+CD25+Foxp3+ Tregs. At the molecular level,
this regulatory effect was, at least in part, mediated by induction
of the inhibitor of DNA binding 3 (Id3) and up-regulation of IL-10
[94]. Interestingly, this tolerogenic mechanism may be usurped
by pathogens to thwart host protective responses as illustrated
by a recent study showing that Trypanosoma cruzi, the etiological
agent of Chagas’ disease, instructs differentiation of tolerogenic
DCs and Foxp3+ Tregs and blunts Th1 and CD8+-mediated anti-
parasite immunity [95]. Moreover, Thiemann et al. have recently
shown a novel mechanism through which Gal-1 blunts DC
responses; the authors demonstrated that this lectin inhibited tis-
sue emigration of immunogenic, but not tolerogenic DCs, through
extracellular matrix and across endothelial cells. This selective
effect appeared to be related to the differential expression of
core-2 O-glycans on CD43 on immunogenic versus tolerogenic
DCs, and to reduced phosphorylation of the protein tyrosine kinase
2 (Pyk2) [96]. Notably, up-regulation of glycosyltransferases
involved in LacNAc synthesis revealed greater sensitivity of mature
versus immature DCs to the immunoregulatory effects of galectins
[97]. However, not only exogenous but also endogenous Gal-1 can
endow DCs with tolerogenic capacity. In fact, Gal-1-expressing DCs
greatly contributed to the resolution of antigen-specific and
autoimmune diseases [93]. Although the precise molecular mech-
anisms involved in this effect still remain to be explored, recent
studies identified CD69 as a counter-receptor for DC-derived Gal-
1 on T cells, suggesting that a Gal-1-CD69 axis may contribute to
DC-mediated suppression of pro-inflammatory T cell responses
[98]. Moreover, DC expression of Gal-1 mediates, at least in part,
the tolerogenic effects triggered by IL-10 and apoptotic cells
[99,100]. Supporting these findings, shRNA-mediated knockdown
of human galectins on DCs, revealed the importance of Gal-1 and
Gal-3, but not Gal-8, in DC suppression of human T cell responses
[101].
Evidence demonstrating the role of endogenous Gal-3 in pro-
moting mouse regulatory DCs was provided by Bernardes et al.
who showed that DCs devoid of this lectin synthesize greater
amounts of IL-12 in response to Toxoplasma gondii infection
[102]. However, in the context of helminth infection, targeting
Gal-3 on DCs enhanced T-cell cytokine responses both in vitro
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Th2 direction [103]. In line with these findings, recent studies
showed that endogenous Gal-3 suppresses Th17 responses during
fungal infections by attenuating secretion of IL-23 on DCs via inhi-
bition of c-Rel/nuclear factor (NF)-j B [104,105]. Thus, at least in
infection models, DC-derived Gal-3 contributes to regulate the
magnitude of Th cytokine responses, suggesting a major regulatory
role of this lectin in regulating the strength and duration of adap-
tive immune responses. Interestingly, elegant studies aimed at elu-
cidating the role of mucins during gut homeostasis showed that
glycans associated with mucin 2 (MUC2) instructed DCs to become
tolerogenic by facilitating the formation of a multimeric complex
formed by Gal-3, the C-type lectin Dectin-1 and the Fc receptor
FccRIIB. Signaling through this receptor complex activates the b-
catenin transcription factor and inhibits transcription of pro-
inflammatory cytokines via a NF-jB-dependent pathway [106].
More recently, it has been demonstrated that, in addition to the
well-established role of this lectin within conventional DC com-
partments, tumor-derived Gal-3 can also shape effector responses
and defeat cancer immunotherapy strategies by limiting the
expansion of plasmacytoid DCs [107].
In contrast to the tolerogenic activities of Gal-1 and Gal-3, expo-
sure of human and mouse DCs to Gal-9 often evoked pro-
inflammatory responses. Accordingly, Gal-9-treated DCs secreted
higher amounts of IL-12, but not IL-10, elicited the production of
Th1 cytokines [108] and increased the number of Tim-3+CD86+
mature DCs [109]. A mechanistic analysis successfully dissected
the paradoxical T cell regulatory and DC proinflammatory activities
of Gal-9, suggesting that the N- and C-terminal CRDs of this lectin
contribute differently to its multiple functions. While Gal-9-C is
implicated in the regulation of T cell survival, the Gal-9-N is much
more effective in activating DCs by inducing higher tumor necrosis
factor (TNF) and IL-6 production and greater p38 mitogen-
activated protein kinase (p38 MAPK)s and Akt phosphorylation
[110]. Collectively, these studies suggest different roles of individ-
ual members of the galectin family in DC biology. Whereas Gal-1
and Gal-3 augment the tolerogenic properties of DCs, exposure to
the tandem-repeat Gal-9 increases the immunogenic potential of
these cells (see Fig. 2). Whether a galectin-specific signature might
delineate the tolerogenic or immunogenic function of DCs is still an
open question.
5. Alternatively-activated M2-type macrophages and microglia
Cells of the monocyte/macrophage lineage are characterized by
their functional diversity and plasticity. In response to a broad
spectrum of stimuli (e.g. TLR agonists, microbial products or
cytokines), tissue macrophages may undergo M1 (pro-
inflammatory or classically-activated) or M2 (anti-inflammatory
or alternatively-activated) polarization [111]. While M1-type
macrophages are associated with antimicrobial responses, antitu-
mor immunity and pathogenic autoimmune inflammation, M2-
type polarization delineates a variety of biological responses
including tissue repair, immunosuppression, promotion of tumor
angiogenesis and metastasis [111]. The presence of interferon
(IFN)-c or bacterial lipopolysaccharides (LPS) endows macro-
phages with M1-type activity, whereas IL-4 and IL-13 skew the
balance toward an M2-type alternatively-activated profile [112].
Interestingly, M1-type macrophages produce high amounts of
nitric oxide (NO) through activation of inducible nitric oxide syn-
thase (iNOS) and secrete greater amounts of pro-inflammatory
cytokines such as TNF, IL-1 and IL-6, favoring cytotoxic responses,
microbial killing and tissue injury. In contrast, polarization toward
an M2-type phenotype involves preferential expression of
arginase-1 and synthesis of IL-10, TGF-b and VEGF [112]. This char-acteristic phenotype of M2-type cells is accompanied by lower
expression of major histocompatibility complex (MHC) II and
CD11b and up-regulated expression of the chitinase-3-like protein
3, also known as Ym1, a lectin with affinity for glycosaminoglycans
such as heparin and heparan sulfate [112]. Interestingly, similar
but not identical polarization profiles have been observed in cells
of the microglial lineage, and dynamic fluctuations of M1/M2 phe-
notypes have been associated with different stages of brain inflam-
matory diseases including multiple sclerosis, Alzheimer’s disease,
Parkinson’s disease and spinal cord injury. Generally, M1-type
microglia have been associated with neurodegenerative and
demyelinating processes, while M2-type microglia are often a hall-
mark of immune resolution, neuroprotection and repair [113].
Identification of the mechanisms, pathways and molecules associ-
ated with macrophage plasticity and polarization provides an
attractive framework for macrophage-centered therapeutic
strategies.
We have identified the presence of Gal-1 in macrophages [114],
its up-regulated expression in response to macrophage activation
[114,115] and its ability to shift the balance toward an M2-type
profile, as shown by suppression of iNOS expression and NO pro-
duction and up-regulation of arginase activity [116]. This inhibitory
function was confirmed in human monocytes, which upon expo-
sure to Gal-1, exhibited a dose-dependent reduction of IFN-c-
induced MHC II expression and MHC II-dependent antigen presen-
tation [117]. Supporting these findings, exposure to Gal-1 inhibited
arachidonic acid release and prostaglandin E2 (PGE2) synthesis
[118] and favored the conversion of macrophages toward a
pro-resolving phenotype, characterized by CD11blow surface
expression, up-regulated activity of the 12/15-lipoxygenase
(a pro-resolving enzyme), loss of phagocytic capacity (efferocytic
satiation) and diminished TNF and IL-1 secretion [119], suggesting
that exogenous Gal-1 may favor alternative M2 activation, de-
activation or promotion of a pro-resolving state within the mono-
cyte/macrophage compartment. In this regard, one might speculate
that phagocytic clearance of dying cells or cells exposing phos-
phatidylserine as a result of Gal-1 treatment, might also contribute
to the generation of M2-type macrophages and restoration of
immune cell homeostasis [120,121]. Supporting these findings,
macrophages from mice lacking the b1,3-N-
acetylglucosaminyltransferase 2 (b3GnT2), an enzyme required
for extending poly-LacNAc residues (specific ligands for galectins),
showed a greater activation profile upon challenge with inflamma-
tory stimuli compared with their wild-type counterpart [122].
Interestingly, in a model of autoimmune neuroinflammation,
we found that astrocytes produce high amounts of Gal-1 which
was sufficient to convert inflammatory M1-type microglia toward
a neuroprotective anti-inflammatory M2-type phenotype. Mecha-
nistically, astrocyte-derived Gal-1 bound to core 2-O-glycans on
CD45, retained this glycoprotein on the surface of microglia cells
and increased its phosphatase activity, thereby promoting micro-
glia de-activation. This effect involved modulation of the p38
MAPK, cyclic adenosine monophosphate (cAMP) response
element-binding (CREB) and NF-jB-dependent pathways and sup-
pression of pro-inflammatory cascades mediated by iNOS, TNF and
the chemokine (C–C motif) ligand 2 (CCL2) [123]. As a result,
alternatively-activated M2 microglia prevented inflammation-
induced neurodegeneration and abrogated the demyelination pro-
cess [123]. This inhibitory effect, together with the direct neuro-
protective role of Gal-1, mediated by the neuropilin-1 (NRP1)-
Plexin A4 complex [124], contributes to promote axonal regenera-
tion, tissue repair and CNS homeostasis. Notably, although exoge-
nous Gal-1 favored an M2 activation phenotype, polarization of
humanmonocytes into M1 or M2 profile was followed by profound
changes in intracellular Gal-3, but not Gal-1 expression [125], sug-
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Within the immune system, Gal-3 was originally defined as
Mac-2 antigen or IgE-binding protein (eBP), and found to be pref-
erentially expressed in tissue macrophages and mast cells [126–
128]. Research over the past few years revealed that, in addition
to the well-established roles of Gal-3 in controlling macrophage
survival and phagocytosis [129,130], this lectin also serves to
induce alternative activation of these cells [131]. Accordingly,
Gal-3 null (Lgals3/) mutant mice showed defects in IL-4/IL-13-
induced alternative macrophage activation in bone marrow-
derived macrophages in vitro and in resident lung and recruited
peritoneal macrophages in vivo, without affecting IFN-c/LPS-
induced classical activation or IL-10-induced deactivation [131].
In contrast, in a model of liver hepatotoxicity, Gal-3 deficiency
resulted in suppression of M1-type pro-inflammatory, but not
M2-type macrophage infiltrates [132]. Likewise, high Gal-3 expres-
sion was found to be a hallmark of M1-type macrophages in pan-
creatic inflammatory infiltrates in a model of type-2 diabetes
[133]. Moreover, in human peripheral blood monocytes, Gal-3
enhanced IL-10 production, thus contributing to de-activation of
these cells [134]. Taken together, these results suggest context-
dependent regulation of monocyte/macrophage polarization by
Gal-3, which could result from the differential expression of pro-
versus anti-inflammatory cytokines in target tissues or the
in vivo evaluation of fresh liver macrophages versus in vitro differ-
entiated bone marrow-derived macrophages.
Interestingly, recent studies by Burguillos and colleagues ele-
gantly showed that Gal-3 serves as an endogenous paracrine ligand
for TLR4 on microglia cells, shifting the balance toward an M1-type
phenotype, which accentuates CNS inflammation [135]. In accor-
dance with these findings, cuprizone (CPZ)-treated mice displayed
heightened M1 microglial activation associated with ectodermal
dysplasia protein 1 (ED1) expression and pronounced upregulation
of the phagocytic triggering receptor expressed on myeloid cells 2
(TREM-2b), while this effect was not observed in CPZ-treated Lgal-
s3/ mice [136]. The pro-inflammatory effects of Gal-3 on micro-
glial cells were found to be mediated by modulation of the Janus
kinase (JAK)-STAT signaling pathway [137]. Likewise, Gal-2 was
found to function as a pro-inflammatory factor that skews human
macrophages toward an M1-like phenotype through binding to
CD14 and activating the TLR4 signaling [138]. This pro-
inflammatory profile was also suggested in earlier studies demon-
strating that Gal-2 expression in macrophages links the
lymphotoxin-a cascade with myocardial infarction [139]. Finally,
although Gal-9 treatment ameliorated autoimmune arthritis,
inhibited FccR expression and expanded immunosuppressive
CD11b+Ly-6C+ macrophages [140], association of Gal-9 with Tim-
3 on microglia cells promoted tissue inflammation in a model of
CNS autoimmunity [141]. These discrepancies could be explained,
at least partly, by cis-association of Gal-9 to Tim-3 within the
macrophage surface, which amplifies TLR signaling and favors
pro-inflammatory responses, as opposed to the inhibitory effects
of Tim-3 upon delivery of this lectin in trans [142]. Thus, distinct
members of the galectin family, function intracellularly or extra-
cellularly, to regulate macrophage polarization and activation
thresholds, thereby influencing the magnitude and resolution of
acute and chronic inflammatory processes (see Fig. 2).
6. Myeloid-derived suppressor cells
Myeloid-derived suppressor cells represent a heterogeneous
population of immature and mature myeloid cells that expand
and accumulate under pathological conditions, such as cancer,
acute and chronic infections, trauma and autoimmune diseases.These cells have been identified in most patients and experimental
tumor models based on their ability to dampen effector T cell
responses [143]. Recently, two major subtypes of MDSCs have been
identified in mice and human, namely granulocytic MDSCs (G-
MDSCs) and monocytic MDSCs (M-MDSCs) based on morphology,
phenotype and functional differences. In mice G-MDSCs have a
CD11b+Ly-6G+Ly-6Clow phenotype, whereas M-MDSCs display a
CD11b+Ly-6GLy-6Chigh phenotype as the Ly-6G molecule is
known to be expressed primarily on granulocytes, whereas Ly-6C
is typically highly expressed on monocytes. On the other hand,
recent studies have implicated CD15 and CD66b as potential mark-
ers allowing discrimination of granulocytic and monocytic MDSCs
in humans. Interestingly, G-MDSCs primarily use reactive oxygen
species (ROS) as the predominant mechanism of immune suppres-
sion, whereas M-MDSCs primarily use NO, arginase and inhibitory
cytokines to blunt T cell responses [144]. Investigation of the stim-
uli that regulate expansion and accumulation of MDSCs in the
blood, lymph nodes and tumor sites, revealed multiple pro-
inflammatory factors including PGE2, IL-1b, IL-6, VEGF and HYPER-
LINK ‘‘https://en.wikipedia.org/wiki/S100_protein” no ‘‘S100 pro-
tein” S100 calcium-binding protein A8/A9 (S100A8/A9),
suggesting a link between inflammation, immunosuppression
and tumor growth [4]. Interestingly, the immunoregulatory activ-
ity of MDSCs can be positively or negatively influenced by a myriad
of tumor-derived cytokines and growth factors or by treatment
with pharmacological agents [143,145]. Thus, targeting MDSCs
either in combination with cancer immunotherapy or vaccination
strategies appears to be a clinically promising strategy to overcome
immunosuppression and potentiate immune responses. In con-
trast, promotion of their expansion or accumulation in inflamed
tissues, may contribute to alleviate undesired responses in settings
of autoimmune inflammation and graft rejection.
Although the impact of galectins within the MDSC compart-
ment has not been studied in such detail as other regulatory cell
populations, Dardalhon and colleagues found that activation of
the Gal-9/Tim-3 pathway increased the number of CD11b+Ly-6G+
G-MDSCs which negatively controlled T cell responses in vivo
[146]. Similarly, in a model of myocarditis, Gal-9 remarkably
increased the frequency of CD11b+Gr-1+ MDSCs in cardiac tissue
and spleens of treated mice, although in this case, a Ly-6C+ M-
MDSC population was favored [147]. Alterations in the frequency
of granulocytic and monocytic MDSCs were recently observed
under Gal-3 deficiency in a mouse model of lung inflammation,
suggesting that Gal-3 also controls the fate of this immunoregula-
tory cell population [148]. Likewise, silencing Gal-1 expression sig-
nificantly decreased the frequency of brain-infiltrating MDSCs in
models of glioblastoma [149]. Finally, a circuit linking microbiota,
tumor-promoting inflammation and immunosuppression via a
galectin-dependent mechanism was recently identified. In TLR5-
responsive tumors, systemic IL-6 induced by commensal bacteria
drove the mobilization of G-MDSCs, which in turn promoted
expansion of Gal-1-secreting cd T lymphocytes, which dampened
antitumor immunity and accelerated malignant progression [58].
Although further evidence is still required, these results suggest
that a coordinated galectin network may act in concert to differen-
tially control MDSC programs (see Fig. 2).
7. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are non-hematopoietic progen-
itor cells with the potential to regenerate tissues and differentiate
into a variety of cell types. They have generated great interest
because of their broad immunomodulatory potential, mainly due
to secretion of soluble factors such as TGF-b, IDO and PGE2, which
could be exploited for the treatment of autoimmune disorders and
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mediators of the immunoregulatory activity of these cells, Gieseke
and colleagues identified Gal-1 as a major contributor to MSCs-
induced immunosuppression. Knocking down Gal-1 in human
MSCs resulted in a significant loss of their immunoregulatory
activity compared with MSCs infected with non-targeting
sequences. Whereas Gal-1 silencing partially restored proliferation
of CD4+ and CD8+ T cells and augmented the release of T-cell
derived cytokines, MSC-induced inhibition of natural killer (NK)
cell activity was unaffected [151]. Interestingly, Gal-1 and Gal-3
were constitutively expressed in MSCs [152], whereas Gal-9 was
readily induced upon exposure to pro-inflammatory or activating
stimuli to inhibit T cell and B cell proliferation [153,154]. In vivo,
Gal-1 also contributed to suppression of acute liver injury induced
by tonsil-derived MSCs [155], and, together with Gal-3, influenced
the immunoregulatory activity of human umbilical cord blood-
derived MSCs [156,157]. These findings suggest that independently
of their tissue origin, MSCs may blunt T-cell responses through
galectin-dependent mechanisms.
8. Conclusions and perspectives
Understanding the environmental stimuli, soluble factors and
molecular networks that govern the induction, differentiation,
accumulation, function and stability of regulatory immune cell
populations is critical to defining the pathophysiology of
immune-mediated diseases and to developing new therapeutic
interventions. In the present review we focus on the relevance of
galectins, an endogenous family of immunoregulatory glycan-
binding proteins, in the fate and function of lymphoid and myeloid
regulatory cells including Tregs (Foxp3+ nTregs, Foxp3+ iTregs and
Foxp3 Tr1 cells), Bregs, tolerogenic DCs, M2-type macrophages,
MDSCs and MSCs. Like many cytokines and growth factors, it is
not surprising that galectins may exhibit a ‘double-edge sword’
effect with opposing biological outcomes depending on different
intrinsic factors such as their concentrations in local tissues, their
extracellular versus intracellular localization, their subcellular
compartmentalization, as well as biochemical features including
the degree of multimerization and their stability in oxidative ver-
sus reducing microenvironments. Moreover, as galectin–glycan
lattices can regulate the dynamics of glycosylated binding partners
and control receptor segregation, internalization and downstream
signaling [18], biochemical factors that govern these cellular
events may also play a role in dictating the stimulatory or inhibi-
tory effects of individual members of the galectin family. Further-
more, since glycosylation patterns and expression of galectin-
specific ligands may differ substantially among different regulatory
cell populations, the overall effect of individual galectins may also
depend on extracellular factors including the activation and differ-
entiation state of target cells and their preferential localization in
different tissues.
In light of the broad spectrum of immunosuppressive effects
and their relevance in re-wiring immune regulatory cell networks,
challenges for the future will embrace a rational manipulation of
galectin–glycan interactions toward attenuating immune
responses in autoimmune diseases, allergic reactions, graft rejec-
tion and recurrent fetal loss. However, before galectin-based ther-
apeutic agents can be extrapolated to clinical settings, a more
thorough understanding of the mechanisms involved in galectin
functions, their distribution and stability in inflamed tissues and
their potential ‘off-target’ effects is required. In this regard, it will
be critical to evaluate the results of side-by-side studies of the
immunomodulatory activities of individual family members on
particular regulatory cell types and to examine their function in
pro-inflammatory and tolerogenic microenvironments.As a reverse side of the same coin, interrupting galectin-
mediated signaling pathways, using glycomimetics, pep-
tidomimetics, small molecule inhibitors, glycodendrimers or neu-
tralizing antibodies, may contribute to overcome
immunosuppression and to potentiate anti-cancer and anti-
microbial host immunity. Finally, a definitive proof-of-concept of
the relevance of galectins in different regulatory compartments
will arise from tissue-specific deletion of individual galectins or
relevant glycosyltransferases and their connection with specific
physiologic or pathologic conditions. Further studies should also
be conducted to identify individuals with relevant primary genetic
defects or polymorphisms associated to inflammatory or neoplas-
tic settings, similarly to those found for Gal-2 gene (LGALS2) in
myocardial infarction [139] and for Gal-3 gene (LGALS3) in breast
cancer [158]. Given the complexity of the galectin network and
their glycosylated and non-glycosylated counter-receptors, as well
as the multiple parameters governing their localization and molec-
ular interactions, further work is warranted to achieve a global
comprehensive view of the relevance of these proteins within reg-
ulatory cell compartments and to dissect their individual roles in
physiologically- and clinically-relevant settings.
Conflict of interest
None declared.
Acknowledgements
We apologize to the many authors whose papers could not be
cited owing to space limitations. Work in G.A.R’s lab is supported
by the Argentinean Agency for Promotion of Science and Technol-
ogy (PICT 2010-870 and PICT 2012-2440), The National Multiple
Sclerosis Society (USA), The National Research Council for Scientific
and Technical Investigation (CONICET), University of Buenos Aires
(UBA) and Fundación Sales. A.G.B is a Fundación Bunge & Born
post-doctoral fellow, S.P.M.H is a CONICET post-graduate fellow,
A.J.C. is a CONICET post-doctoral fellow and G.A.R. is CONICET
career researcher.
References
[1] Abbas, A.K.L., A., H. and Pillai, S. (2014) Basic Immunology: Functions and
Disorders of the Immune System, fourth ed, Elsevier, Philadelphia.
[2] Roychoudhuri, R., Eil, R.L. and Restifo, N.P. (2015) The interplay of effector
and regulatory T cells in cancer. Curr. Opin. Immunol. 33, 101–111.
[3] Chaudhry, A. and Rudensky, A.Y. (2013) Control of inflammation by
integration of environmental cues by regulatory T cells. J. Clin. Invest. 123,
939–944.
[4] Ostrand-Rosenberg, S. and Sinha, P. (2009) Myeloid-derived suppressor cells:
linking inflammation and cancer. J. Immunol. 182, 4499–4506.
[5] Steinman, R.M. (2012) Decisions about dendritic cells: past, present, and
future. Ann. Rev. Immunol. 30, 1–22.
[6] Mills, C.D. (2015) Anatomy of a discovery: M1 and M2 macrophages. Front.
Immunol. 6, 212.
[7] Miyagaki, T., Fujimoto, M. and Sato, S. (2015) Regulatory B cells in human
inflammatory and autoimmune diseases: from mouse models to clinical
research. Int. Immunol. (in press).
[8] Uccelli, A., Moretta, L. and Pistoia, V. (2006) Immunoregulatory function of
mesenchymal stem cells. Eur. J. Immunol. 36, 2566–2573.
[9] Terness, P., Kallikourdis, M., Betz, A.G., Rabinovich, G.A., Saito, S. and Clark, D.
A. (2007) Tolerance signaling molecules and pregnancy: IDO, galectins, and
the renaissance of regulatory T cells. Am. J. Reprod. Immunol. 58, 238–254.
[10] Hoeppli, R.E., Wu, D., Cook, L. and Levings, M.K. (2015) The environment of
regulatory T cell biology: cytokines, metabolites, and the microbiome. Front.
Immunol. 6, 61.
[11] Rabinovich, Gabriel A. and Croci, Diego O. (2012) Regulatory circuits
mediated by lectin–glycan interactions in autoimmunity and cancer.
Immunity 36, 322–335.
[12] Vasta, G.R. (2012) Galectins as pattern recognition receptors: structure,
function, and evolution. Adv. Exp. Med. Biol. 946, 21–36.
[13] Mehul, B. and Hughes, R.C. (1997) Plasma membrane targetting, vesicular
budding and release of galectin 3 from the cytoplasm of mammalian cells
during secretion. J. Cell Sci. 110, 1169–1178.
A.G. Blidner et al. / FEBS Letters 589 (2015) 3407–3418 3415[14] Rabinovich, G.A. and Toscano, M.A. (2009) Turning ‘sweet’ on immunity:
galectin–glycan interactions in immune tolerance and inflammation. Nat.
Rev. Immunol. 9, 338–352.
[15] Cummings, R.D. and E., J. (2009) in: Principles of Glycan Recognition in
Essentials of Glycobiology (Varki, A., Ed.), Cold Spring Harbor Laboratory
Press, Ney York.
[16] Dam, T.K. and Brewer, C.F. (2010) Lectins as pattern recognition molecules:
the effects of epitope density in innate immunity. Glycobiology 20,
270–279.
[17] Croci, D.O., Cerliani, J.P., Pinto, N.A., Morosi, L.G. and Rabinovich, G.A. (2014)
Regulatory role of glycans in the control of hypoxia-driven angiogenesis and
sensitivity to anti-angiogenic treatment. Glycobiology 24, 1283–1290.
[18] Elola, María T., Blidner, Ada G., Ferragut, F., Bracalente, C. and Rabinovich,
Gabriel A. (2015) Assembly, organization and regulation of cell-surface
receptors by lectin–glycan complexes. Biochem. J. 469, 1–16.
[19] Liu, F.-T., Patterson, R.J. and Wang, J.L. (2002) Intracellular functions of
galectins. Biochim. Biophys. Acta (BBA) – Gen. Subj. 1572, 263–273.
[20] Thurston, T.L.M., Wandel, M.P., von Muhlinen, N., Foeglein, A. and Randow, F.
(2012) Galectin 8 targets damaged vesicles for autophagy to defend cells
against bacterial invasion. Nature 482, 414–418.
[21] Johannes, L., Parton, R.G., Bassereau, P. and Mayor, S. (2015) Building
endocytic pits without clathrin. Nat. Rev. Mol. Cell Biol. 16, 311–321.
[22] Fred Brewer, C. (2002) Binding and cross-linking properties of galectins.
Biochim. Biophys. Acta (BBA) – Gen. Subj. 1572, 255–262.
[23] Dennis, J.W., Nabi, I.R. and Demetriou, M. (2009) Metabolism, cell surface
organization, and disease. Cell 139, 1229–1241.
[24] Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Mendez-Huergo, S.P.,
Mascanfroni, I.D., Dergan-Dylon, S., Toscano, M.A., Caramelo, J.J., Garcia-
Vallejo, J.J., Ouyang, J., Mesri, E.A., Junttila, M.R., Bais, C., Shipp, M.A., Salatino,
M. and Rabinovich, G.A. (2014) Glycosylation-dependent lectin-receptor
interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156,
744–758.
[25] Hirabayashi, J., Hashidate, T., Arata, Y., Nishi, N., Nakamura, T., Hirashima, M.,
Urashima, T., Oka, T., Futai, M., Muller, W.E.G., Yagi, F. and Kasai, K.-I. (2002)
Oligosaccharide specificity of galectins: a search by frontal affinity
chromatography. Biochim. Biophys. Acta (BBA) – Gen. Subj. 1572, 232–254.
[26] Stowell, S.R., Arthur, C.M., Mehta, P., Slanina, K.A., Blixt, O., Leffler, H., Smith,
D.F. and Cummings, R.D. (2008) Galectin-1, -2, and -3 exhibit differential
recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 283,
10109–10123.
[27] Di Lella, S., Sundblad, V., Cerliani, J.P., Guardia, C.M., Estrin, D.A., Vasta, G.R.
and Rabinovich, G.A. (2011) When galectins recognize glycans: from
biochemistry to physiology and back again. Biochemistry 50, 7842–7857.
[28] Cooper, D., Ilarregui, J.M., Pesoa, S.A., Croci, D.O., Perretti, M. and Rabinovich,
G.A. (2010) Multiple functional targets of the immunoregulatory activity of
galectin-1: control of immune cell trafficking, dendritic cell physiology, and
t-cell fate. Meth. Enzymol. 480, 199–244.
[29] Cedeno-Laurent, F. and Dimitroff, C.J. (2012) Galectins and their ligands:
negative regulators of anti-tumor immunity. Glycoconj. J. 29, 619–625.
[30] Mendez-Huergo, S.P., Maller, S.M., Farez, M.F., Mariño, K., Correale, J. and
Rabinovich, G.A. (2014) Integration of lectin–glycan recognition systems and
immune cell networks in CNS inflammation. Cytokine Growth Factor Rev. 25,
247–255.
[31] Cerliani, J., Stowell, S., Mascanfroni, I., Arthur, C., Cummings, R. and
Rabinovich, G. (2011) Expanding the universe of cytokines and pattern
recognition receptors: galectins and glycans in innate immunity. J. Clin.
Immunol. 31, 10–21.
[32] Zeng, H., Zhang, R., Jin, B. and Chen, L. (2015) Type 1 regulatory T cells: a new
mechanism of peripheral immune tolerance. Cell. Mol. Immunol. (in press).
[33] Sugimoto, N., Oida, T., Hirota, K., Nakamura, K., Nomura, T., Uchiyama, T. and
Sakaguchi, S. (2006) Foxp3-dependent and -independent molecules specific
for CD25+CD4+ natural regulatory T cells revealed by DNA microarray
analysis. Int. Immunol. 18, 1197–1209.
[34] Garín, M.I., Chu, C.-C., Golshayan, D., Cernuda-Morollón, E., Wait, R. and
Lechler, R.I. (2006) Galectin-1: a key effector of regulation mediated by
CD4+CD25+ T cells. Blood 109, 2058–2065.
[35] Baatar, D., Olkhanud, P.B., Wells, V., Indig, F.E., Mallucci, L. and Biragyn, A.
(2009) Tregs utilize b-galactoside-binding protein to transiently inhibit PI3K/
p21(ras) activity of human CD8(+) T cells to block their TCR-mediated ERK
activity and proliferation. Brain Behav. Immun. 23, 1028–1037.
[36] Wang, J., Lu, Z.-H., Gabius, H.-J., Rohowsky-Kochan, C., Ledeen, R.W. and Wu,
G. (2009) Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory
T cell activity involving TRPC5 channel activation: possible role in
suppressing experimental autoimmune encephalomyelitis. J. Immunol. 182,
4036–4045.
[37] Ocklenburg, F., Moharregh-Khiabani, D., Geffers, R., Janke, V., Pfoertner, S.,
Garritsen, H., Groebe, L., Klempnauer, J., Dittmar, K.E.J., Weiss, S., Buer, J. and
Probst-Kepper, M. (2006) UBD, a downstream element of FOXP3, allows the
identification of LGALS3, a new marker of human regulatory T cells. Lab.
Invest. 86, 724–737.
[38] Kubach, J., Lutter, P., Bopp, T., Stoll, S., Becker, C., Huter, E., Richter, C.,
Weingarten, P., Warger, T., Knop, J., Müllner, S., Wijdenes, J., Schild, H.,
Schmitt, E. and Jonuleit, H. (2007) Human CD4+CD25+ regulatory T cells:
proteome analysis identifies galectin-10 as a novel marker essential for their
anergy and suppressive function. Blood 110, 1550–1558.[39] Wang, F., Wan, L., Zhang, C., Zheng, X., Li, J. and Chen, Z.K. (2009) Tim-3-
Galectin-9 pathway involves the suppression induced by CD4+CD25+
regulatory T cells. Immunobiology 214, 342–349.
[40] Ju, Y., Shang, X., Liu, Z., Zhang, J., Li, Y., Shen, Y., Liu, Y., Liu, C., Liu, B., Xu, L.,
Wang, Y., Zhang, B. and Zou, J. (2014) The Tim-3/galectin-9 pathway involves
in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-
induced hepatitis. Mol. Immunol. 58, 85–91.
[41] Kared, H., Fabre, T., Bédard, N., Bruneau, J. and Shoukry, N.H. (2013) Galectin-
9 and IL-21 mediate cross-regulation between Th17 and Treg cells during
acute hepatitis C. PLoS Pathog. 9, e1003422.
[42] Wu, C., Thalhamer, T., Franca, Rafael F., Xiao, S., Wang, C., Hotta, C., Zhu, C.,
Hirashima, M., Anderson, Ana C. and Kuchroo, Vijay K. (2014) Galectin-9-
CD44 interaction enhances stability and function of adaptive regulatory T
cells. Immunity 41, 270–282.
[43] Rabinovich, G.A., Daly, G., Dreja, H., Tailor, H., Riera, C.M., Hirabayashi, J. and
Chernajovsky, Y. (1999) Recombinant galectin-1 and its genetic delivery
suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190,
385–398.
[44] Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez,
J.D., Zwirner, N.W., Poirier, F., Riley, E.M., Baum, L.G. and Rabinovich, G.A.
(2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells
selectively regulates susceptibility to cell death. Nat. Immunol. 8, 825–834.
[45] Toscano, M.A., Commodaro, A.G., Ilarregui, J.M., Bianco, G.A., Liberman, A.,
Serra, H.M., Hirabayashi, J., Rizzo, L.V. and Rabinovich, G.A. (2006) Galectin-1
suppresses autoimmune retinal disease by promoting concomitant Th2- and
T regulatory-mediated anti-inflammatory responses. J. Immunol. 176, 6323–
6332.
[46] Perone, M.J., Larregina, A.T., Shufesky, W.J., Papworth, G.D., Sullivan, M.L.G.,
Zahorchak, A.F., Stolz, D.B., Baum, L.G., Watkins, S.C., Thomson, A.W. and
Morelli, A.E. (2006) Transgenic galectin-1 induces maturation of dendritic
cells that elicit contrasting responses in naive and activated T CELLS. J.
Immunol. 176, 7207–7220.
[47] Santucci, L., Fiorucci, S., Rubinstein, N., Mencarelli, A., Palazzetti, B., Federici,
B., Rabinovich, G.A. and Morelli, A. (2003) Galectin-1 suppresses
experimental colitis in mice. Gastroenterology 124, 1381–1394.
[48] Pérez, C.V., Gómez, L.G., Gualdoni, G.S., Lustig, L., Rabinovich, G.A. and
Guazzone, V.A. (2015) Dual roles of endogenous and exogenous galectin-1 in
the control of testicular immunopathology. Sci. Rep. 5.
[49] Baum, L.G., Blackall, D.P., Arias-Magallano, S., Nanigian, D., Uh, S.Y., Browne, J.
M., Hoffmann, D., Emmanouilides, C.E., Territo, M.C. and Baldwin, G.C. (2003)
Amelioration of graft versus host disease by galectin-1. Clin. Immunol. 109,
295–307.
[50] Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo,
A., Mordoh, J., Fainboim, L., Podhajcer, O.L. and Rabinovich, G.A. (2004)
Targeted inhibition of galectin-1 gene expression in tumor cells results in
heightened T cell-mediated rejection: a potential mechanism of tumor-
immune privilege. Cancer Cell 5, 241–251.
[51] Banh, A., Zhang, J., Cao, H., Bouley, D.M., Kwok, S., Kong, C., Giaccia, A.J.,
Koong, A.C. and Le, Q.T. (2011) Tumor galectin-1 mediates tumor growth and
metastasis through regulation of T-cell apoptosis. Cancer Res. 71, 4423–4431.
[52] Martínez-Bosch, N., Fernández-Barrena, M.G., Moreno, M., Ortiz-Zapater, E.,
Munné-Collado, J., Iglesias, M., André, S., Gabius, H.-J., Hwang, R.F. and Poirier,
F. (2014) Galectin-1 drives pancreatic carcinogenesis through stroma
remodeling and Hedgehog signaling activation. Cancer Res. 74, 3512–3524.
[53] Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J.,
Chen, W., Kutok, J.L., Rabinovich, G.A. and Shipp, M.A. (2007) The AP1-
dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune
privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. U.S.A. 104,
13134–13139.
[54] Soldati, R., Berger, E., Zenclussen, A.C., Jorch, G., Lode, H.N., Salatino, M.,
Rabinovich, G.A. and Fest, S. (2012) Neuroblastoma triggers an
immunoevasive program involving galectin-1-dependent modulation of T
cell and dendritic cell compartments. Int. J. Cancer 131, 1131–1141.
[55] Dalotto-Moreno, T., Croci, D.O., Cerliani, J.P., Martinez-Allo, V.C., Dergan-
Dylon, S., Méndez-Huergo, S.P., Stupirski, J.C., Mazal, D., Osinaga, E., Toscano,
M.A., Sundblad, V., Rabinovich, G.A. and Salatino, M. (2013) Targeting
galectin-1 overcomes breast cancer-associated immunosuppression and
prevents metastatic disease. Cancer Res. 73, 1107–1117.
[56] Croci, D.O., Salatino, M., Rubinstein, N., Cerliani, J.P., Cavallin, L.E., Leung, H.J.,
Ouyang, J., Ilarregui, J.M., Toscano, M.A., Domaica, C.I., Croci, M.C., Shipp, M.A.,
Mesri, E.A., Albini, A. and Rabinovich, G.A. (2012) Disrupting galectin-1
interactions with N-glycans suppresses hypoxia-driven angiogenesis and
tumorigenesis in Kaposi’s sarcoma. J. Exp. Med. 209, 1985–2000.
[57] Baker, G.J., Chockley, P., Yadav, V.N., Doherty, R., Ritt, M., Sivaramakrishnan,
S., Castro, M.G. and Lowenstein, P.R. (2014) Natural killer cells eradicate
galectin-1 deficient glioma in the absence of adaptive immunity. Cancer Res.
74, 5079–5090.
[58] Rutkowski, Melanie R., Stephen, Tom L., Svoronos, N., Allegrezza, Michael J.,
Tesone, Amelia J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X.,
Nguyen, Jenny M., Cadungog, Mark G., Zhang, R., Salatino, M., Tchou, J.,
Rabinovich, Gabriel A. and Conejo-Garcia, Jose R. (2015) Microbially driven
TLR5-dependent signaling governs distal malignant progression through
tumor-promoting inflammation. Cancer Cell 27, 27–40.
[59] Salatino, M., Croci, D.O., Bianco, G.A., Ilarregui, J.M., Toscano, M.A. and
Rabinovich, G.A. (2007) Galectin-1 as a potential therapeutic target in
autoimmune disorders and cancer. Exp. Opin. Biol. Ther. 8, 45–57.
3416 A.G. Blidner et al. / FEBS Letters 589 (2015) 3407–3418[60] Liu, S.D., Lee, S., Cava, A.L., Motran, C.C., Hahn, B.H. and Miceli, M.C. (2011)
Galectin-1-induced down-regulation of T lymphocyte activation protects
(NZB  NZW) F1 mice from lupus-like disease. Lupus 20, 473–484.
[61] Blois, S.M., Ilarregui, J.M., Tometten, M., Garcia, M., Orsal, A.S., Cordo-Russo,
R., Toscano, M.A., Bianco, G.A., Kobelt, P., Handjiski, B., Tirado, I., Markert, U.R.,
Klapp, B.F., Poirier, F., Szekeres-Bartho, J., Rabinovich, G.A. and Arck, P.C.
(2007) A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 13,
1450–1457.
[62] Ramhorst, R.E., Giribaldi, L., Fraccaroli, L., Toscano, M.A., Stupirski, J.C.,
Romero, M.D., Durand, E.S., Rubinstein, N., Blaschitz, A., Sedlmayr, P., Genti-
Raimondi, S., Fainboim, L. and Rabinovich, G.A. (2012) Galectin-1 confers
immune privilege to human trophoblast: implications in recurrent fetal loss.
Glycobiology 22, 1374–1386.
[63] Kopcow, H.D., Rosetti, F., Leung, Y., Allan, D.S.J., Kutok, J.L. and Strominger, J.L.
(2008) T cell apoptosis at the maternal–fetal interface in early human
pregnancy, involvement of galectin-1. Proc. Natl. Acad. Sci. U.S.A. 105,
18472–18477.
[64] Seropian, I.M., Cerliani, J.P., Toldo, S., Van Tassell, B.W., Ilarregui, J.M.,
González, G.E., Matoso, M., Salloum, F.N., Melchior, R., Gelpi, R.J., Stupirski, J.
C., Benatar, A., Gómez, K.A., Morales, C., Abbate, A. and Rabinovich, G.A.
(2013) Galectin-1 controls cardiac inflammation and ventricular remodeling
during acute myocardial infarction. Am. J. Path. 182, 29–40.
[65] Stowell, S.R., Qian, Y., Karmakar, S., Koyama, N.S., Dias-Baruffi, M., Leffler, H.,
McEver, R.P. and Cummings, R.D. (2008) Differential roles of galectin-1 and
galectin-3 in regulating leukocyte viability and cytokine secretion. J.
Immunol. 180, 3091–3102.
[66] Sampson, J.F., Hasegawa, E., Mulki, L., Suryawanshi, A., Jiang, S., Chen, W.-S.,
Rabinovich, G.A., Connor, K.M. and Panjwani, N. (2015) Galectin-8
ameliorates murine autoimmune ocular pathology and promotes a
regulatory T cell response. PLoS ONE 10, e0130772.
[67] Sampson, J.F.S., Amol, Chen, Wei-Sheng, Rabinovich, Gabriel, A. and Panjwani,
Noorjahan (2015) Galectin-8 promotes regulatory T-cell differentiation by
modulating IL-2 and TGFb signaling. Immunol. Cell Biol. (in press).
[68] Seki, M., Oomizu, S., Sakata, K.-M., Sakata, A., Arikawa, T., Watanabe, K., Ito, K.,
Takeshita, K., Niki, T., Saita, N., Nishi, N., Yamauchi, A., Katoh, S., Matsukawa,
A., Kuchroo, V. and Hirashima, M. (2008) Galectin-9 suppresses the
generation of Th17, promotes the induction of regulatory T cells, and
regulates experimental autoimmune arthritis. Clin. Immunol. 127, 78–88.
[69] Lv, K., Xu, W., Wang, C., Niki, T., Hirashima, M. and Xiong, S. (2011) Galectin-9
administration ameliorates CVB3 induced myocarditis by promoting the
proliferation of regulatory T cells and alternatively activated Th2 cells. Clin.
Immunol. 140, 92–101.
[70] Ji, X.J., Ma, C.J., Wang, J.M., Wu, X.Y., Niki, T., Hirashima, M., Moorman, J.P. and
Yao, Z.Q. (2013) Immunomodulatory role of the hepatocyte during HCV
infection: driving CD4(+)CD25(+)Foxp3(+) regulatory T cell development
through the Tim-3/Gal-9 pathway. Eur. J. Immunol. 43, 458–467.
[71] de Kivit, S., Kraneveld, A.D., Knippels, L.M.J., van Kooyk, Y., Garssen, J. and
Willemsen, L.E.M. (2013) Intestinal epithelium-derived galectin-9 is involved
in the immunomodulating effects of nondigestible oligosaccharides. J. Innate
Immun. 5, 625–638.
[72] Lu, X., McCoy, K.S., Xu, J., Hu, W., Chen, H., Jiang, K., Han, F., Chen, P. and
Wang, Y. (2015) Galectin-9 ameliorates respiratory syncytial virus-induced
pulmonary immunopathology through regulating the balance between Th17
and regulatory T cells. Virus Res. 195, 162–171.
[73] Lv, Zhang, Zhang, Zhong and Suo (2013) Galectin-9 promotes TGF-b-
dependent induction of regulatory T cells via the TGF-b/Smad signaling
pathway. Mol. Med. Rep. 7, 205–210.
[74] Jiang, H.-R., Al Rasebi, Z., Mensah-Brown, E., Shahin, A., Xu, D., Goodyear, C.S.,
Fukada, S.Y., Liu, F.-T., Liew, F.Y. and Lukic, M.L. (2009) Galectin-3 deficiency
reduces the severity of experimental autoimmune encephalomyelitis. J.
Immunol. 182, 1167–1173.
[75] Fermino, M.L., Dias, F.C., Lopes, C.D., Souza, M.A., Cruz, Â.K., Liu, F.-T.,
Chammas, R., Roque-Barreira, M.C., Rabinovich, G.A. and Bernardes, E.S.
(2013) Galectin-3 negatively regulates the frequency and function of
CD4+CD25+Foxp3+ regulatory T cells and influences the course of
Leishmania major infection. Eur. J. Immunol. 43, 1806–1817.
[76] Rosser, Elizabeth C. and Mauri, C. (2015) Regulatory B cells: origin,
phenotype, and function. Immunity 42, 607–612.
[77] Zuñiga, E., Rabinovich, G.A., Iglesias, M.M. and Gruppi, A. (2001) Regulated
expression of galectin-1 during B-cell activation and implications for T-cell
apoptosis. J. Leukoc. Biol. 70, 73–79.
[78] Yu, X., Siegel, R. and Roeder, R.G. (2006) Interaction of the B cell-specific
transcriptional coactivator OCA-B and galectin-1 and a possible role in
regulating BCR-mediated B cell proliferation. J. Biol. Chem. 281, 15505–
15516.
[79] Croci, D.O., Morande, P.E., Dergan-Dylon, S., Borge, M., Toscano, M.A.,
Stupirski, J.C., Bezares, R.F., Avalos, J.S., Narbaitz, M., Gamberale, R.,
Rabinovich, G.A. and Giordano, M. (2013) Nurse-like cells control the
activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia
27, 1413–1416.
[80] Tsai, C.-M., Wu, H.-Y., Su, T.-H., Kuo, C.-W., Huang, H.-W., Chung, C.-H., Chen,
C.-S., Khoo, K.-H., Chen, Y.-J. and Lin, K.-I. (2014) Phosphoproteomic analyses
reveal that galectin-1 augments the dynamics of B-cell receptor signaling. J.
Proteome 103, 241–253.
[81] Clark, A.G., Chen, S., Zhang, H., Brady, G.F., Ungewitter, E.K., Bradley, J.K.,
Sackey, F.N. and Foster, M.H. (2007) Multifunctional regulators of cell growthare differentially expressed in anergic murine B cells. Mol. Immunol. 44,
1274–1285.
[82] Clark, A.G., Weston, M.L. and Foster, M.H. (2013) Lack of galectin-1 or
galectin-3 alters B cell deletion and anergy in an autoantibody transgene
model. Glycobiology 23, 893–903.
[83] Tabrizi, S.J., Niiro, H., Masui, M., Yoshimoto, G., Iino, T., Kikushige, Y.,
Wakasaki, T., Baba, E., Shimoda, S., Miyamoto, T., Hara, T. and Akashi, K.
(2009) T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell
death pathways in human naive and IgM+ memory B cells through altering
balances in Bcl-2 family proteins. J. Immunol. 182, 1490–1499.
[84] Tsai, C.-M., Chiu, Y.-K., Hsu, T.-L., Lin, I.Y., Hsieh, S.-L. and Lin, K.-I. (2008)
Galectin-1 promotes immunoglobulin production during plasma cell
differentiation. J. Immunol. 181, 4570–4579.
[85] Anginot, A., Espeli, M., Chasson, L., Mancini, S.J.C. and Schiff, C. (2013)
Galectin 1 modulates plasma cell homeostasis and regulates the humoral
immune response. J. Immunol. 190, 5526–5533.
[86] Moritoki, M., Kadowak, T., Niki, T., Nakano, D., Soma, G., Mori, H., Kobara, H.,
Masaki, T., Kohno, M. and Hirashima, M. (2013) Galectin-9 ameliorates
clinical severity of MRL/lpr Lupus-Prone mice by inducing plasma cell
apoptosis independently of Tim-3. PLoS ONE 8, 1–10.
[87] Acosta-Rodríguez, E.V., Montes, C.L., Motrán, C.C., Zuniga, E.I., Liu, F.-T.,
Rabinovich, G.A. and Gruppi, A. (2004) Galectin-3 mediates IL-4-induced
survival and differentiation of B cells: functional cross-talk and implications
during Trypanosoma cruzi infection. J. Immunol. 172, 493–502.
[88] Oliveira, F.L., Chammas, R., Ricon, L., Fermino, M.L., Bernardes, E.S., Hsu, D.K.,
Liu, F.-T., Borojevic, R. and El-Cheikh, M.C. (2009) Galectin-3 regulates
peritoneal B1-cell differentiation into plasma cells. Glycobiology 19, 1248–
1258.
[89] Bonzi, J., Bornet, O., Betzi, S., Kasper, B.T., Mahal, L.K., Mancini, S.J., Schiff, C.,
Sebban-Kreuzer, C., Guerlesquin, F. and Elantak, L. (2015) Pre-B cell receptor
binding to galectin-1 modifies galectin-1/carbohydrate affinity to modulate
specific galectin-1/glycan lattice interactions. Nat. Commun. 6, 6194.
[90] Kim, S.J. and Diamond, B. (2015) Modulation of tolerogenic dendritic cells
and autoimmunity. Semin. Cell Dev. Biol. 41, 49–58.
[91] Rutella, S., Danese, S. and Leone, G. (2006) Tolerogenic dendritic cells:
cytokine modulation comes of age. Blood 108, 1435–1440.
[92] Ilarregui, J.M. and Rabinovich, G.A. (2010) Tolerogenic dendritic cells in the
control of autoimmune neuroinflammation: an emerging role of protein–
glycan interactions. NeuroImmunoModulation 17, 157–160.
[93] Ilarregui, J.M., Croci, D.O., Bianco, G.A., Toscano, M.A., Salatino, M.,
Vermeulen, M.E., Geffner, J.R. and Rabinovich, G.A. (2009) Tolerogenic
signals delivered by dendritic cells to T cells through a galectin-1-driven
immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat.
Immunol. 10, 981–991.
[94] Kuo, P.-L., Hung, J.-Y., Huang, S.-K., Chou, S.-H., Cheng, D.-E., Jong, Y.-J., Hung,
C.-H., Yang, C.-J., Tsai, Y.-M., Hsu, Y.-L. and Huang, M.-S. (2011) Lung cancer-
derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA
binding 3/IL-10 signaling pathway. J. Immunol. 186, 1521–1530.
[95] Poncini, C.V., Ilarregui, J.M., Batalla, E.I., Engels, S., Cerliani, J.P., Cucher, M.A.,
van Kooyk, Y., González Cappa, S.M. and Rabinovich, G.A. (2015) Trypanosoma
cruzi infection imparts a regulatory program in dendritic cells and T cells via
galectin-1-dependent mechanisms. J. Immunol. (in press).
[96] Thiemann, S., Man, J.H., Chang, M.H., Lee, B. and Baum, L.G. (2015) Galectin-1
regulates tissue exit of specific dendritic cell populations. J. Biol. Chem. (in
press).
[97] Bax, M., García-Vallejo, J.J., Jang-Lee, J., North, S.J., Gilmartin, T.J., Hernández,
G., Crocker, P.R., Leffler, H., Head, S.R., Haslam, S.M., Dell, A. and van Kooyk, Y.
(2007) Dendritic cell maturation results in pronounced changes in glycan
expression affecting recognition by siglecs and galectins. J. Immunol. 179,
8216–8224.
[98] de la Fuente, H., Cruz-Adalia, A., Martinez del Hoyo, G., Cibrián-Vera, D.,
Bonay, P., Pérez-Hernández, D., Vázquez, J., Navarro, P., Gutierrez-Gallego, R.,
Ramirez-Huesca, M., Martín, P. and Sánchez-Madrid, F. (2014) The leukocyte
activation receptor CD69 controls T cell differentiation through its
interaction with galectin-1. Mol. Cell. Biol. 34, 2479–2487.
[99] Zhou, F., Ciric, B., Li, H., Yan, Y., Li, K., Cullimore, M., Lauretti, E., Gonnella, P.,
Zhang, G.-X. and Rostami, A. (2012) IL-10 deficiency blocks the ability of LPS
to regulate expression of tolerance-related molecules on dendritic cells. Eur.
J. Immunol. 42, 1449–1458.
[100] Zhou, F., Lauretti, E., di Meco, A., Ciric, B., Gonnella, P., Zhang, G.-X. and
Rostami, A. (2013) Intravenous transfer of apoptotic cell-treated dendritic
cells leads to immune tolerance by blocking Th17 cell activity.
Immunobiology 218, 1069–1076.
[101] Mobergslien, A. and Sioud, M. (2012) Galectin-1 and -3 gene silencing in
immature and mature dendritic cells enhances T cell activation and
interferon-c production. J. Leukoc. Biol. 91, 461–467.
[102] Bernardes, E.S., Silva, N.M., Ruas, L.P., Mineo, J.R., Loyola, A.M., Hsu, D.K., Liu,
F.-T., Chammas, R. and Roque-Barreira, M.C. (2006) Toxoplasma gondii
infection reveals a novel regulatory role for galectin-3 in the interface of
innate and adaptive immunity. Am. J. Pathol. 168, 1910–1920.
[103] Breuilh, L., Vanhoutte, F., Fontaine, J., van Stijn, C.M.W., Tillie-Leblond, I.,
Capron, M., Faveeuw, C., Jouault, T., van Die, I., Gosset, P. and Trottein, F.
(2007) Galectin-3 modulates immune and inflammatory responses during
helminthic infection: impact of galectin-3 deficiency on the functions of
dendritic cells. Infect. Immun. 75, 5148–5157.
A.G. Blidner et al. / FEBS Letters 589 (2015) 3407–3418 3417[104] Fermin Lee, A., Chen, H.-Y., Wan, L., Wu, S.-Y., Yu, J.-S., Huang, A.C., Miaw, S.-
C., Hsu, D.K., Wu-Hsieh, B.A. and Liu, F.-T. (2013) Galectin-3 modulates Th17
responses by regulating dendritic cell cytokines. Am. J. Pathol. 183, 1209–
1222.
[105] Wu, S.-Y., Yu, J.-S., Liu, F.-T., Miaw, S.-C. andWu-Hsieh, B.A. (2013) Galectin-3
negatively regulates dendritic cell production of IL-23/IL-17–axis cytokines
in infection by Histoplasma capsulatum. J. Immunol. 190, 3427–3437.
[106] Shan, M., Gentile, M., Yeiser, J.R., Walland, A.C., Bornstein, V.U., Chen, K., He,
B., Cassis, L., Bigas, A., Cols, M., Comerma, L., Huang, B., Blander, J.M., Xiong,
H., Mayer, L., Berin, C., Augenlicht, L.H., Velcich, A. and Cerutti, A. (2013)
Mucus enhances gut homeostasis and oral tolerance by delivering
immunoregulatory signals. Science 342, 447–453.
[107] Kouo, T., Huang, L., Pucsek, A.B., Cao, M., Solt, S., Armstrong, T. and Jaffee, E.
(2015) Galectin-3 shapes antitumor immune responses by suppressing CD8+
T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells.
Cancer Immunol. Res. 3, 412–423.
[108] Dai, S.-Y., Nakagawa, R., Itoh, A., Murakami, H., Kashio, Y., Abe, H., Katoh, S.,
Kontani, K., Kihara, M., Zhang, S.-L., Hata, T., Nakamura, T., Yamauchi, A. and
Hirashima, M. (2005) Galectin-9 induces maturation of human monocyte-
derived dendritic cells. J. Immunol. 175, 2974–2981.
[109] Nagahara, K., Arikawa, T., Oomizu, S., Kontani, K., Nobumoto, A., Tateno, H.,
Watanabe, K., Niki, T., Katoh, S., Miyake, M., Nagahata, S.-I., Hirabayashi, J.,
Kuchroo, V.K., Yamauchi, A. and Hirashima, M. (2008) Galectin-9 increases
Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via
galectin-9-Tim-3 interactions. J. Immunol. 181, 7660–7669.
[110] Li, Y., Feng, J., Geng, S., Geng, S., Wei, H., Chen, G., Li, X., Wang, L., Wang, R.,
Peng, H., Han, G., Shen, B. and Li, Y. (2011) The N- and C-terminal
carbohydrate recognition domains of galectin-9 contribute differently to its
multiple functions in innate immunity and adaptive immunity. Mol.
Immunol. 48, 670–677.
[111] Sica, A. and Mantovani, A. (2012) Macrophage plasticity and polarization:
in vivo veritas. J. Clin. Invest. 122, 787–795.
[112] Martinez, F.O. and Gordon, S. (2014) The M1 and M2 paradigm of
macrophage activation: time for reassessment. F1000 Prime Rep. 6, 13.
[113] Franco, R. and Fernández-Suárez, D. (2015) Alternatively activated microglia
and macrophages in the central nervous system. Prog. Neurobiol. 131, 65–86.
[114] Rabinovich, G., Castagna, L., Landa, C., Riera, C.M. and Sotomayor, C. (1996)
Regulated expression of a 16-kd galectin-like protein in activated rat
macrophages. J. Leukoc. Biol. 59, 363–370.
[115] Rabinovich, G.A., Iglesias, M.M., Modesti, N.M., Castagna, L.F., Wolfenstein-
Todel, C., Riera, C.M. and Sotomayor, C.E. (1998) Activated rat macrophages
produce a galectin-1-like protein that induces apoptosis of T cells:
biochemical and functional characterization. J. Immunol. 160, 4831–4840.
[116] Correa, S.G., Sotomayor, C.E., Aoki, M.P., Maldonado, C.A. and Rabinovich, G.A.
(2003) Opposite effects of galectin-1 on alternative metabolic pathways of L-
arginine in resident, inflammatory, and activated macrophages. Glycobiology
13, 119–128.
[117] Barrionuevo, P., Beigier-Bompadre, M., Ilarregui, J.M., Toscano, M.A., Bianco,
G.A., Isturiz, M.A. and Rabinovich, G.A. (2007) A novel function for galectin-1
at the crossroad of innate and adaptive immunity: galectin-1 regulates
monocyte/macrophage physiology through a nonapoptotic ERK-dependent
pathway. J. Immunol. 178, 436–445.
[118] Rabinovich, G.A., Sotomayor, C.E., Riera, C.M., Bianco, I. and Correa, S.G.
(2000) Evidence of a role for galectin-1 in acute inflammation. Eur. J.
Immunol. 30, 1331–1339.
[119] Rostoker, R., Yaseen, H., Schif-Zuck, S., Lichtenstein, R.G., Rabinovich, G.A. and
Ariel, A. (2013) Galectin-1 induces 12/15-lipoxygenase expression in murine
macrophages and favors their conversion toward a pro-resolving phenotype.
Prostaglandins Other Lipid Mediat. 107, 85–94.
[120] Pang, M., He, J., Johnson, P. and Baum, L.G. (2009) CD45 mediated fodrin
cleavage during galectin-1 mediated T cell death promotes phagocytic
clearance of dying cells. J. Immunol. 182, 7001–7008.
[121] Dias-Baruffi, M., Zhu, H., Cho, M., Karmakar, S., McEver, R.P. and Cummings,
R.D. (2003) Dimeric galectin-1 induces surface exposure of
phosphatidylserine and phagocytic recognition of leukocytes without
inducing apoptosis. J. Biol. Chem. 278, 41282–41293.
[122] Togayachi, A., Kozono, Y., Ishida, H., Abe, S., Suzuki, N., Tsunoda, Y., Hagiwara,
K., Kuno, A., Ohkura, T., Sato, N., Sato, T., Hirabayashi, J., Ikehara, Y.,
Tachibana, K. and Narimatsu, H. (2007) Polylactosamine on glycoproteins
influences basal levels of lymphocyte and macrophage activation. Proc. Natl.
Acad. Sci. U.S.A. 104, 15829–15834.
[123] Starossom, Sarah C., Mascanfroni, Ivan D., Imitola, J., Cao, L., Raddassi, K.,
Hernandez, Silvia F., Bassil, R., Croci, Diego O., Cerliani, Juan P., Delacour, D.,
Wang, Y., Elyaman, W., Khoury, Samia J. and Rabinovich, Gabriel A. (2012)
Galectin-1 deactivates classically activated microglia and protects from
inflammation-induced neurodegeneration. Immunity 37, 249–263.
[124] Quinta, H.R., Pasquini, J.M., Rabinovich, G.A. and Pasquini, L.A. (2014) Glycan-
dependent binding of galectin-1 to neuropilin-1 promotes axonal
regeneration after spinal cord injury. Cell Death Differ. 21, 941–955.
[125] Novak, R., Dabelic, S. and Dumic, J. (2012) Galectin-1 and galectin-3
expression profiles in classically and alternatively activated human
macrophages. Biochim. Biophys. Acta (BBA) – Gen. Subj. 1820, 1383–1390.
[126] Sato, S. and Hughes, R.C. (1994) Regulation of secretion and surface
expression of Mac-2, a galactoside-binding protein of macrophages. J. Biol.
Chem. 269, 4424–4430.[127] Frigeri, L.G. and Liu, F.T. (1992) Surface expression of functional IgE binding
protein, an endogenous lectin, on mast cells and macrophages. J. Immunol.
148, 861–867.
[128] Sundblad, V., Croci, D.O. and Rabinovich, G.A. (2011) Regulated expression of
galectin-3, a multifunctional glycan-binding protein, in haematopoietic and
non-haematopoietic tissues. Histol. Histopathol. 26, 1–19.
[129] Hsu, D.K., Yang, R.-Y., Pan, Z., Yu, L., Salomon, D.R., Fung-Leung, W.-P. and Liu,
F.-T. (2000) Targeted disruption of the galectin-3 gene results in attenuated
peritoneal inflammatory responses. Am. J. Pathol. 156, 1073–1083.
[130] Sano, H., Hsu, D.K., Apgar, J.R., Yu, L., Sharma, B.B., Kuwabara, I., Izui, S. and
Liu, F.-T. (2003) Critical role of galectin-3 in phagocytosis by macrophages. J.
Clin. Invest. 112, 389–397.
[131] MacKinnon, A.C., Farnworth, S.L., Hodkinson, P.S., Henderson, N.C., Atkinson,
K.M., Leffler, H., Nilsson, U.J., Haslett, C., Forbes, S.J. and Sethi, T. (2008)
Regulation of alternative macrophage activation by galectin-3. J. Immunol.
180, 2650–2658.
[132] Dragomir, A.-C.D., Sun, R., Choi, H., Laskin, J.D. and Laskin, D.L. (2012) Role of
galectin-3 in classical and alternative macrophage activation in the liver
following acetaminophen intoxication. J. Immunol. 189, 5934–5941.
[133] Cucak, H., Grunnet, L.G. and Rosendahl, A. (2014) Accumulation of M1-like
macrophages in type 2 diabetic islets is followed by a systemic shift in
macrophage polarization. J. Leukoc. Biol. 95, 149–160.
[134] Chung, A.W., Sieling, P.A., Schenk, M., Teles, R.M.B., Krutzik, S.R., Hsu, D.K.,
Liu, F.-T., Sarno, E.N., Rea, T.H., Stenger, S., Modlin, R.L. and Lee, D.J. (2013)
Galectin-3 regulates the innate immune response of human monocytes. J.
Infect. Dis. 207, 947–956.
[135] Burguillos, Miguel A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-
Quintanilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, Maria
J., Osman, Ahmed M., Salomonsson, E., Amar, L., Persson, A., Blomgren, K.,
Achour, A., Englund, E., Leffler, H., Venero, Jose L., Joseph, B. and Deierborg, T.
(2015) Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and
contributes to microglial activation. Cell Rep. 10, 1626–1638.
[136] Hoyos, H.C., Rinaldi, M., Mendez-Huergo, S.P., Marder, M., Rabinovich, G.A.,
Pasquini, J.M. and Pasquini, L.A. (2014) Galectin-3 controls the response of
microglial cells to limit cuprizone-induced demyelination. Neurobiol. Dis. 62,
441–455.
[137] Jeon, S.-B., Yoon, H.J., Chang, C.Y., Koh, H.S., Jeon, S.-H. and Park, E.J. (2010)
Galectin-3 exerts cytokine-like regulatory actions through the JAK–STAT
pathway. J. Immunol. 185, 7037–7046.
[138] Yıldırım, C., Vogel, D.Y.S., Hollander, M.R., Baggen, J.M., Fontijn, R.D.,
Nieuwenhuis, S., Haverkamp, A., de Vries, M.R., Quax, P.H.A., Garcia-Vallejo,
J.J., van der Laan, A.M., Dijkstra, C.D., van der Pouw Kraan, T.C.T.M., van
Royen, N. and Horrevoets, A.J.G. (2015) Galectin-2 induces a
proinflammatory, anti-arteriogenic phenotype in monocytes and
macrophages. PLoS ONE 10, e0124347.
[139] Ozaki, K., Inoue, K., Sato, H., Iida, A., Ohnishi, Y., Sekine, A., Sato, H., Odashiro,
K., Nobuyoshi, M., Hori, M., Nakamura, Y. and Tanaka, T. (2004) Functional
variation in LGALS2 confers risk of myocardial infarction and regulates
lymphotoxin-[alpha] secretion in vitro. Nature 429, 72–75.
[140] Arikawa, T., Saita, N., Oomizu, S., Ueno, M., Matsukawa, A., Katoh, S., Kojima,
K., Nagahara, K., Miyake, M., Yamauchi, A., Kohrogi, H. and Hirashima, M.
(2010) Galectin-9 expands immunosuppressive macrophages to ameliorate
T-cell-mediated lung inflammation. Eur. J. Immunol. 40, 548–558.
[141] Anderson, A.C., Anderson, D.E., Bregoli, L., Hastings, W.D., Kassam, N., Lei, C.,
Chandwaskar, R., Karman, J., Su, E.W., Hirashima, M., Bruce, J.N., Kane, L.P.,
Kuchroo, V.K. and Hafler, D.A. (2007) Promotion of tissue inflammation by
the immune receptor Tim-3 expressed on innate immune cells. Science 318,
1141–1143.
[142] Ma, C.J., Li, G.Y., Cheng, Y.Q., Wang, J.M., Ying, R.S., Shi, L., Wu, X.Y., Niki, T.,
Hirashima, M., Li, C.F., Moorman, J.P. and Yao, Z.Q. (2013) Cis association of
galectin-9 with Tim-3 differentially regulates IL-12/IL-23 expressions in
monocytes via TLR signaling. PLoS ONE 8, e72488.
[143] Gabrilovich, D.I., Ostrand-Rosenberg, S. and Bronte, V. (2012) Coordinated
regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268.
[144] Youn, J.I. and Gabrilovich, D.I. (2010) The biology of myeloid-derived
suppressor cells: the blessing and the curse of morphological and
functional heterogeneity. Eur. J. Immunol. 40, 2969–2975.
[145] Blidner, A.G., Salatino, M., Mascanfroni, I.D., Diament, M.J., de Kier, Bal., Joffé,
E., Jasnis, M.A., Klein, S.M. and Rabinovich, G.A. (2015) Differential response
of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory
agent indomethacin in tumor-associated and tumor-free
microenvironments. J. Immunol. 194, 3452–3462.
[146] Dardalhon, V., Anderson, A.C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D.
H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F.J., Sobel, R.A., Hirashima,
M. and Kuchroo, V.K. (2010) Tim-3/galectin-9 pathway: regulation of Th1
immunity through promotion of CD11b(+)Ly-6G(+) myeloid cells. J.
Immunol. 185, 1383–1392.
[147] Zhang, Y., Jiang, L., Zhang, M. and Lv, K. (2014) Galectin-9 induced myeloid
suppressor cells expand regulatory T cells in an IL-10-dependent manner in
CVB3-induced acute myocarditis. Int. J. Mol. Sci. 15, 3356–3372.
[148] Sunil, V.R., Francis, M., Vayas, K.N., Cervelli, J.A., Choi, H., Laskin, J.D. and
Laskin, D.L. (2015) Regulation of ozone-induced lung inflammation and
injury by the b-galactoside-binding lectin galectin-3. Toxicol. Appl. Pharm.
284, 236–245.
[149] Verschuere, T., Toelen, J., Maes, W., Poirier, F., Boon, L., Tousseyn, T., Mathivet,
T., Gerhardt, H., Mathieu, V., Kiss, R., Lefranc, F., Van Gool, S.W. and
3418 A.G. Blidner et al. / FEBS Letters 589 (2015) 3407–3418Vleeschouwer, A. (2008) Glioma-derived galectin-1 regulates innate and
adaptive antitumor immunity. Int. J. Cancer 134, 873–884.
[150] Uccelli, A. and de Rosbo, N.K. (2015) The immunomodulatory function of
mesenchymal stem cells: mode of action and pathways. Ann. N.Y. Acad. Sci..
[151] Gieseke, F., Böhringer, J., Bussolari, R., Dominici, M., Handgretinger, R. and
Müller, I. (2010) Human multipotent mesenchymal stromal cells use
galectin-1 to inhibit immune effector cells. Blood 116, 3770–3779.
[152] Sioud, M., Mobergslien, A., Boudabous, A. and Floisand, Y. (2011)
Mesenchymal stem cell-mediated T cell suppression occurs through
secreted galectins. Int. J. Oncol. 38, 385–390.
[153] Gieseke, F., Kruchen, A., Tzaribachev, N., Bentzien, F., Dominici, M. and
Müller, I. (2013) Proinflammatory stimuli induce galectin-9 in human
mesenchymal stromal cells to suppress T-cell proliferation. Eur. J.
Immunol. 43, 2741–2749.
[154] Ungerer, C., Quade-Lyssy, P., Radeke, H.H., Henschler, R., Königs, C., Köhl, U.,
Seifried, E. and Schüttrumpf, J. (2014) Galectin-9 is a suppressor of T and B
cells and predicts the immune modulatory potential of mesenchymal
stromal cell preparations. Stem Cells Dev. 23, 755–766.[155] Ryu, K.-H., Kim, S.-Y., Kim, Y.-R., Woo, S.-Y., Sung, S.H., Kim, H.S., Jung, S.-C.,
Jo, I. and Park, J.-W. (2014) Tonsil-derived mesenchymal stem cells alleviate
concanavalin A-induced acute liver injury. Exp. Cell Res. 326, 143–154.
[156] Suila, H., Hirvonen, T., Kotovuori, A., Ritamo, I., Kerkelä, E., Anderson, H.,
Natunen, S., Tuimala, J., Laitinen, S., Nystedt, J., Räbinä, J. and Valmu, L. (2014)
Human umbilical cord blood-derived mesenchymal stromal cells display a
novel interaction between P-selectin and galectin-1. Scan. J. Immunol. 80,
12–21.
[157] Liu, G., Wang, L., Pang, T., Zhu, D., Xu, Y., Wang, H., Cong, X. and Liu, Y. (2014)
Umbilical cord-derived mesenchymal stem cells regulate thymic epithelial
cell development and function in Foxn1/ mice. Cell. Mol. Immunol. 11,
275–284.
[158] Balan, V., Nangia-Makker, P., Schwartz, A.G., Jung, Y.S., Tait, L., Hogan, V., Raz,
T., Yi, W., Yang, Z.Q., Wu, G.S., Guo, Y., Li, H., Abrams, J., Couch, F.J., Lingle, W.
L., Lloyd, R.V., Ethier, S.P., Tainsky, M. and Raz, A. (2008) Racial disparity in
breast cancer and functional germ line mutation in galectin-3 (rs4644): a
pilot study. Cancer Res. 68, 10045–10050.
